The APS Phenotyping Study
A legfontosabb adatok
- Ki végzi
- Vanderbilt University Medical Center
- Hol
- Ann Arbor, Baltimore, Chicago, Cincinnati, Denver, Durham, Fresno, Loveland, Murray, Nashville, Palo Alto, Philadelphia, Salt Lake City, San Francisco és St Louis (Egyesült Államok)Mind a 20 helyszín megnézése
- Azonosító
- Állapot
- Toboroz
- Résztvevők
- 4000 fő, tervezett
- Kezdés
- 2024. júl. 25.
- Várható befejezés
- 2029. ápr. 30.
- A vizsgálat típusa
- Megfigyeléses, 3 csoport
- A vizsgált kezelések
- Blood collection
- Urine Collection
- Nasal, oral, and rectal swabs
- Stool collection
- Heat Moisture Exchange Filter collection
- Tracheal Aspirate sample collection
- Non-bronchoscopic bronchoalveolar lavage (NBBAL)
- Surveys
- Short physical performance battery
- Hand grip strength
- CNS Vital Signs
- Muscle Ultrasound
- Muscle Strength
- Spirometry
- Lung Diffusion Testing (DLCO)
- Chest CT Scan
- A regiszteradat frissítve
- 2026. február 20.
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 18 feltétel megnézéseKevesebb
Ki vehet részt
- To be eligible for enrollment, a patient must meet all the following inclusion criteria at the time of the first study-specified biospecimen collection (Time 0):
- Age ≥ 18 years old
- Admitted (or planned to be admitted) to an intensive care unit (ICU) or other in-patient hospital location where IV vasopressors or advanced respiratory support (invasive mechanical ventilation, non-invasive ventilation, or high flow nasal cannula) are routinely provided (referred to as an "eligible unit.")
- Acute cardiovascular or pulmonary organ dysfunction defined by meeting at least one of the two criteria below:; New receipt of invasive mechanical ventilation, non-invasive ventilation, high flow nasal cannula, or supplemental oxygen at a flow rate of ≥ 6 lpm for acute hypoxemia; Patients who use chronic oxygen therapy are eligible to participate if they are receiving at least 6 lpm higher than their baseline oxygen requirement (e.g., a patient on 3 lpm O2 at baseline is eligible if they require ≥9 lpm for hypoxemia) or are started on advanced respiratory support (invasive mechanical ventilation, non- invasive ventilation, or high flow nasal cannula); Receipt of intravenous infusion of a vasopressor medication for at least one hour
- Acute cardiovascular or pulmonary organ dysfunction (inclusion criterion #3) is attributed to an acute inflammatory condition, including but not limited to any of the following:; Any infection including pneumonia; Aspiration pneumonitis; Pancreatitis; Auto-inflammatory condition such as:; Hemophagocytic lymphohistiocytosis; Suspected acute rheumatologic or auto-immune disease with pulmonary or cardiovascular manifestations; Suspected cryptogenic organizing pneumonia presenting acutely; Suspected diffuse alveolar hemorrhage; Suspected acute anaphylaxis; Suspected acute pulmonary drug toxicity
Ki nem vehet részt
- Patient had out-of-hospital cardiac arrest leading to this hospitalization
- Presence of tracheostomy for respiratory failure
- Home invasive mechanical ventilation or non-invasive ventilation (except patients with non-invasive ventilation prescribed as a treatment for a sleep disorder may participate)
- Suspected cause of the patient's acute cardiovascular and/or pulmonary dysfunction (inclusion criterion #3) is an alternative condition (not ARDS, pneumonia, or sepsis), including but not limited to the list below:; Drug overdose (without aspiration, lung injury, pneumonia, or infection); Trauma (without aspiration, pneumonia, or infection); Chronic lung disease without suspected infection, aspiration, or inflammation; Asthma, chronic obstructive pulmonary disease (COPD), sarcoidosis, interstitial lung disease, neuromuscular respiratory failure; Status epilepticus; Acute pulmonary embolism; Acute decompensated heart failure; Diabetic ketoacidosis; Acute stroke or intracranial hemorrhage; Acute bleeding (GI bleeding, post-procedural bleeding, hemolysis); Cytokine release syndrome due to chemotherapy
- Inability or unwillingness to complete study-specified blood draws, for example, due to local policies about hemoglobin thresholds for research blood draws
- To be eligible for enrollment, a patient must not meet any of the following exclusion criteria at the time of the first study-specified biospecimen collection (Time 0):
- Patient/legally authorized representative (LAR) declines participation
- Acute cardiovascular or pulmonary organ dysfunction (inclusion criterion #3) has been present for > 48 hours
- Patient has been in an eligible unit (inclusion criterion #2) for more than 120 hours (five days)
- Patient is no longer expected to meet the acute cardiovascular or pulmonary organ dysfunction inclusion criterion (inclusion criterion #3) 24 hours after enrollment
- Patient desires comfort measures only
- Patient is a prisoner
- Residence immediately before this hospitalization in a long-term acute care facility
Helyszínek itt: Egyesült Államok
- University of MichiganAnn Arbor, Egyesült ÁllamokContact: Robert Hyzy, MDRésztvevőt keres
- Johns Hopkins UniveristyBaltimore, Egyesült ÁllamokContact: Dale Needham, MD, PhDRésztvevőt keres
- Northwestern Memorial HospitalChicago, Egyesült ÁllamokContact: Richard Wunderink, MDRésztvevőt keres
- University of ChicagoChicago, Egyesült ÁllamokContact: Krysta Wolfe, MDRésztvevőt keres
- University of CincinnatiCincinnati, Egyesült ÁllamokContact: R. Duncan Hite, MDRésztvevőt keres
- Denver Health and Hospital AuthorityDenver, Egyesült ÁllamokContact: Jason Mansoori, MDRésztvevőt keres
- National Jewish HealthDenver, Egyesült ÁllamokContact: William Janssen, MDRésztvevőt keres
- University of Colorado DenverDenver, Egyesült ÁllamokContact: Marc Moss, MDRésztvevőt keres
- Duke UniversityDurham, Egyesült ÁllamokContact: Christina Barkauskas, MDRésztvevőt keres
- Fresno Community Hospital and Medical CenterFresno, Egyesült ÁllamokContact: Eyad Almasri, MDRésztvevőt keres
- UC Health Medical Center of the RockiesLoveland, Egyesült ÁllamokContact: Eric Stevens, MDRésztvevőt keres
- Intermountain Medical CenterMurray, Egyesült ÁllamokContact: Samuel Brown, MD, MSRésztvevőt keres
- Meharry Medical CollegeNashville, Egyesült ÁllamokContact: Richard Freemont, MDRésztvevőt keres
- Vanderbilt University Medical CenterNashville, Egyesült ÁllamokContact: Wesley H. Self, MDRésztvevőt keres
- Stanford UniversityPalo Alto, Egyesült ÁllamokContact: Angela Rogers, MDRésztvevőt keres
- University of PennsylvaniaPhiladelphia, Egyesült ÁllamokContact: Nuala Meyer, MD, MSRésztvevőt keres
- University of UtahSalt Lake City, Egyesült ÁllamokContact: Estelle Harris, MDRésztvevőt keres
- San Francisco General HospitalSan Francisco, Egyesült ÁllamokContact: Carolyn Hendrickson, MD, MPHRésztvevőt keres
- University of California San FranciscoSan Francisco, Egyesült ÁllamokContact: Carolyn Calfee, MDRésztvevőt keres
- Washington University School of MedicineSt Louis, Egyesült ÁllamokContact: Pratik Sinha, MBChB, PhDRésztvevőt keres
A vizsgálatról
Mit akar kideríteni a vizsgálat
The goal of the observational APS phenotyping study is to better understand risk factors, potential biomarkers, length and severity of illness, and recovery for adults with ARDS, pneumonia, and/ or sepsis. This study will also generate a biobank of specimens collected from these patients that will be available to investigators for future studies of ARDS, sepsis, and/or pneumonia.
A vizsgálat 3 csoportja
- Cohort A (full study protocol - written informed consent)
Cohort A is the cohort of APS study participants who have provided written informed consent for participation in the APS phenotyping study. Cohort A may participate in all study procedures in the APS phenotyping study.
Kezelés: Blood collection, Urine Collection, Nasal, oral, and rectal swabs, Stool collection, Heat Moisture Exchange Filter collection, Tracheal Aspirate sample collection, Non-bronchoscopic bronchoalveolar lavage (NBBAL) és Surveys
- Cohort B (alteration study protocol - alteration of informed consent)
Cohort B is the cohort of APS study participants who are enrolled in the study under alteration of informed consent. Cohort B will participate in a modified set of procedures which omits procedures considered greater than minimal risk.
Kezelés: Blood collection, Urine Collection, Nasal, oral, and rectal swabs, Stool collection, Heat Moisture Exchange Filter collection és Tracheal Aspirate sample collection
- Long-term Outcomes Cohort
The Long-term Outcomes Cohort consists of a subset of participants with written informed consent for study participation (Cohort A) who complete in-person post-hospital study assessments. These in-person study visits are scheduled at 3- and 12-months after initial enrollment in the hospital. Interventions/exposures are denoted for this group for study procedures that are completed during an in-person post-hospital visit.
Kezelés: Blood collection, Nasal, oral, and rectal swabs, Stool collection, Short physical performance battery, Hand grip strength, CNS Vital Signs, Muscle Ultrasound, Muscle Strength, Spirometry, Lung Diffusion Testing (DLCO) és Chest CT Scan
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- The ARDS, Pneumonia, and Sepsis (APS) Consortium: A Prospective Observational Study to Evaluate Phenotypes
- Publikációk
- A regiszteradat frissítve
- 2026. február 20.